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Aim: Stenotrophomonas maltophilia (Sm) and Burkholderia cepacia complex (BCC) 25	
are gram-negative bacterial pathogens, which are typically multi-drug resistant and 26	
excellent biofilm producers. These phenotypes are controlled by quorum sensing (QS) 27	
systems from the DSF (Diffusible Signal Factor) family. We aim to interfere with this QS 28	
system as an alternative approach in combatting such difficult-to-treat infections. 29	
Materials & methods: A library of sulfonamide-based DSF bioisosteres was 30	
synthesised and tested against the major phenotypes regulated by QS. Results and 31	
Conclusion: Several analogues display significant antibiofilm activity while the majority 32	
increase the action of the last-resort antibiotic colistin against Sm and BCC. Most 33	
compounds inhibit DSF synthesis in the Sm K279a strain. Our results support the 34	




Members of the Stenotrophomonas maltophilia (Sm) and the Burkholderia cepacia  37	
complexes (BCC) are gram-negative bacterial species from different orders that share 38	
several common characteristics [1]. Although both bacterial complexes are mostly 39	
ubiquitous and frequently associated with plants [2–5], they are also recognised as 40	
important nosocomial and cystic fibrosis (CF) pathogens [6–9]. As human pathogens, 41	
these bacteria seem to have a preference for respiratory tract infections [10]. Other 42	
relevant major traits shared by Sm and BCC include their elevated ability to form 43	
biofilms on biotic and abiotic surfaces -including medical devices- and their high degree 44	
of antimicrobial resistance, isolates of which are typically multidrug resistant (MDR) 45	
[11].  46	
In addition, both pathogens regulate bacterial behaviour such as virulence in response 47	
to their population density through similar quorum sensing (QS) systems mediated by 48	
the fatty acid signals of the DSF (diffusible signal factor) family [12–14]. 49	
 50	
Antimicrobial resistance (AMR) is acknowledged as the biggest challenge in modern 51	
medicine, since the rapid emergence of MDR isolates, including pan-resistant 52	
pathogens, significantly hampers the effective treatment of infected patients [15,16].  53	
To overcome AMR, innovative approaches have been proposed. For example, novel 54	
antimicrobial adjuvants may rescue the activity of current antimicrobials and limit the 55	
onset of resistance [17]. Compounds targeting virulence represent another promising 56	
alternative [18–20]. For those pathogens which produce biofilms in a clinical context, 57	
antibiofilm agents are also being explored [21].  58	
QS or bacterial cell-to-cell communication [22], is a major regulatory hub for virulence, 59	
biofilm formation and AMR [23,24]. Strategies targeting QS mechanisms have attracted 60	
considerable interest in recent years, as the blocking of key components of QS signal 61	
synthesis or perception can significantly attenuate microbial virulence [25]. 62	
Sm and BCC utilise similar QS signals based on the DSF family which are comprised 63	
of cis-unsaturated fatty acids [12–14]. The major QS signal in Sm is DSF or cis-11-64	
methyl-2-dodecenoic acid [26,27]. BCC produces a closely related molecule, namely 65	
BDSF (Burkholderia diffusible signal factor), whose structure is cis-2-dodecenoic acid 66	
[28,29]. DSF and BDSF are almost identical, differing only by the presence of a methyl 67	
group on C11 in DSF (Figure 1).  68	
Although general mechanisms of DSF regulation apply to all bacteria displaying DSF-69	
like communication, there are considerable differences between species but also within 70	
a species at a subpopulation level, as exemplified by Sm rpf-1 and rpf-2 groups. A 71	
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schematic illustration of the key components governing DSF and BDSF regulation in 72	
Sm and BCC, respectively, is presented in Figure 1.  73	
 74	
Figure 1. A) In the Sm rpf-1 system, RpfC-1 promotes RpfF-1 basal activity 75	
synthesizing DSF (cis-11-methyl-2-dodecenoic acid) that diffuses towards the 76	
extracellular environment. When the DSF concentration is high, RpfC-1 senses the 77	
signalling molecule and consequently phosphorylates the phosphodiesterase RpfG. 78	
RpFG then converts cyclic diguanylate monophosphate (c-di-GMP) to GMP thereby 79	
controlling the expression of genes which regulate biofilm formation, virulence and 80	
bacterial motility.  81	
B) In the Sm rpf-2 system, RpfC-2  blocks RpfF-2, which in turns stops DSF synthesis. 82	
Exogenous DSF signals released by surrounding bacteria (e.g., rpf-1 strain) are 83	
detected by RpfC-2 liberating active RpfF-2 to produce DSF and thus stimulating 84	
bacterial virulence. 85	
C) In BCC, BDSF (cis-2-dodecenoic acid) communication is governed by an unrelated 86	
cluster composed of the synthase RpfF and the receptor RpfR. When the concentration 87	
of BDSF is high, RpfR senses BDSF and promotes its c-di-GMP phosphodiesterases 88	
activity reducing intracellular levels of c-di-GMP and allowing the RpfR–GtrR complex 89	
to regulate the expression of genes involved in virulence.  90	
 91	
Certain QS signals may also exert a collateral effect on surrounding microorganisms. 92	
For example, the Pseudomonas Quinolone Signal (PQS), and its precursor 4-hydroxy-93	
2-heptylquinoline (HHQ), display antimicrobial activity against various bacteria and 94	
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yeasts [30,31]. Likewise, DSF and structurally similar fatty acids potentiate the activity 95	
of different antibiotics against a wide range of bacterial pathogens [32]. In 96	
Xanthomonas campestris, DSF is involved in biofilm dispersal [34]. The related fatty 97	
acid cis-2-decenoic acid (cis-DA) produced by Pseudomonas aeruginosa also 98	
promotes biofilm dispersion in several bacterial species [34]. Additionally, both BDSF 99	
and DSF inhibit hyphal transition of Candida albicans most probably by acting as 100	
antagonists of the DSF-related C. albicans signal farnesoic acid [29,35].  101	
It has previously been reported that the cis-unsaturated double bond between C2 and 102	
C3 in DSF is a prerequisite for activity, since both the corresponding trans-unsaturated 103	
fatty acid and the fully saturated analogue produce significantly weaker biological 104	
responses [36]. Furthermore, the perceptive bacteria appear to be sensitive to 105	
shortening or elongation of the carbon backbone. These findings suggest that 106	
medicinal agents based on DSF or BDSF should avoid major changes to these 107	
structural features. For this reason, we wondered if replacing the carboxylic acid group 108	
with an appropriate sulfonamide might be worthy of investigation. Sulfonamides are 109	
considered bioisosteres of carboxylic acids and have a proven track record in 110	
medicinal chemistry [37]. Compounds modified in this fashion may display greater 111	
selectivity, less side effects, increased lipophilicity, decreased toxicity, improved 112	
pharmacokinetics or a reversal of agonistic/antagonist activity [38]. Sulfonamide 113	
derivatives of DSF or BDSF might be expected to disrupt cell-cell signalling and 114	
thereby constitute novel QS inhibitors [39]. 115	
Herein, we describe our work on the synthesis of a series of DSF and BDSF 116	
sulfonamide-based bioisosteres for testing against MDR isolates of the pathogens Sm 117	
and BCC, including strains resistant to the last-resort antibiotic colistin. We include our 118	
findings on the antibiofilm activity of these compounds as well as their ability to 119	
potentiate the effect of colistin both in vitro and in vivo	 using the Galleria mellonella 120	
infection model. We also investigate their potential anti-QS activity and lastly, we 121	





General procedure for the preparation of acylsulfonamides 3a-3d: 125	
A solution of dodec-2-ynoic acid (2a - 200 mg, 1.02 mmol, 1.0 eq) and the appropriate 126	
sulfonamide (1.1 mmol, 1.1 eq) in 10 mL dry dichloromethane was cooled to 0° C. 127	
DMAP (134 mg, 1.1 mmol, 1.1 eq) was then added at once. The mixture was stirred at 128	
0° C for 15 min. EDCI (170 mg, 1.1 mmol, 1.1 eq) was added and gradually the 129	
temperature was raised to 25° C. Stirring was continued at this temperature for 16 h. 130	
After completion of the reaction, dichloromethane was added (20 mL), followed by 2M 131	
aqueous HCl solution (20 mL) and stirring continued for 30 sec (solution should reach 132	
pH 2-3). The organic layer was separated, dried over MgSO4 and solvent was then 133	
removed by vacuum distillation. The crude mixture was purified by column 134	
chromatography on silica gel using CH2Cl2-MeOH (100:0-98:2). 135	
 136	
N-(Methylsulfonyl)dodec-2-ynamide (3a) 137	
Yield: 36%  138	
1H NMR:  (400 MHz, CDCl3) 0.88 (t, 3H, J = 6.62 Hz), 1.23 – 1.43 (m, 12H), 1.52 – 139	
1.62 (m, 2H), 2.36 (t, 2H; J = 7.07 Hz), 3.33 (s, 3H), 8.21 (bs, 1H). 140	
13C NMR: δ (100 MHz, CDCl3): 4.11, 18.79, 22.66, 27.34, 28.86, 29.00, 29.24, 29.37, 141	
31.83, 41.77, 73.54, 94.46, 150.53. 142	
IR:  (cm-1): 3197, 2963, 2922, 2848, 2220, 1688, 1666, 1437, 1405, 1225, 1156, 1067, 143	
974, 874, 619. 144	
HRMS (ESI-TOF) m/z: [M – 1] Calcd for C13H22NO3S 272.1326; Found 272.1314. 145	
 146	
N-(Phenylsulfonyl)dodec-2-ynamide (3b) 147	
Yield: 48%  148	
1H NMR:  (400 MHz, CDCl3) 0.80 (t, 3H, J = 6.64), 1.09 – 1.31 (m, 12H), 1.40 – 1.49 149	
(m, 2H), 2.22 (t, 2H, J = 7.08 Hz), 7.49 (t, 2H, J = 7.73 Hz), 7.60 (t, 1H, J = 7.42 Hz), 150	
7.97 – 8.02 (m, 2H). 151	
13C NMR: δ (100 MHz, CDCl3): 14.11, 18.75, 22.65, 27.32, 28.83, 28.98, 29.23, 29.34, 152	
31.82, 73.68, 94.02, 128.49, 129.05, 134.25, 138.19, 149.51. 153	
IR:  (cm-1): 3215, 2924, 2854, 2226, 1670, 1449, 1431, 1350, 1217, 1160, 1088, 1056, 154	
866, 813, 685. 155	
HRMS (ESI-TOF) m/z: [M – 1] Calcd for C18H24NO3S 334.1482; Found 334.1477. 156	
 157	
N-((2-Bromophenyl)sulfonyl)dodec-2-ynamide (3c) 158	
Yield: 67%  159	
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1H NMR:  (400 MHz, CDCl3): 0.88 (t, 3H, J = 6.72 Hz), 1.19 – 1.40 (m, 12H), 1.50 – 160	
1.58 (m, 2H), 2.31 (t, 2H; J = 7.11 Hz), 7.46 – 7.55 (m, 2H), 7.76 (dd, 1H, J = 1.71, 161	
7.38 Hz), 8.30 (dd, 1H, J = 1.93, 7.74 Hz), 8.40 (bs, 1H). 162	
13C NMR: δ (100 MHz, CDCl3): 14.12, 18.83, 22.66, 27.29, 28.84, 28.99, 29.24, 29.37, 163	
31.84, 73.46, 94.70, 120.21, 127.80, 133.42, 135.05, 135.29, 137.34, 149.19. 164	
IR:  (cm-1): 3203, 2916, 2848, 2226, 1694, 1574, 1425, 1350, 1260, 1223, 1162, 1125, 165	
1050, 832, 762. 166	
HRMS (ESI-TOF) m/z: [M – 1] Calcd for C18H23NO3SBr 412.0588; Found 412.0580. 167	
 168	
N-(Cyclopropylsulfonyl)dodec-2-ynamide (3d) 169	
Yield: 50%  170	
1H NMR:  (400 MHz, CDCl3): 0.88 (t, 3H, J = 7.09 Hz), 1.11 – 1.18 (m, 2H), 1.19 – 171	
1.45 (m, 14H), 1.53 – 1.65 (m, 2H), 2.35 (t, 2H; J = 7.22 Hz), 2.94 (tt, 1H; J = 3.40, 172	
4.84 Hz), 7.92 (bs, 1H). 173	
13C NMR: δ (100 MHz, CDCl3): 6.46, 14.11, 18.80, 22.66, 27.38, 28.88, 29.01, 29.24, 174	
29.37, 31.50, 31.84, 73.70, 77.23, 150.16. 175	
IR:  (cm-1): 3389, 3193, 2918, 2230, 1698, 1456, 1435, 1343, 1315, 1294, 1221, 1188, 176	
1060, 883, 705. 177	
HRMS (ESI-TOF) m/z: [M + 1] Calcd for C15H26NO3S 300.1628; Found 300.1626. 178	
 179	
General procedure for the preparation of acylsulfonamide 3e-3h: 180	
A solution of 11-methyldodec-2-ynoic acid (2b) (350 mg, 1.664 mmol), DMAP (226 mg, 181	
1.850 mmol, 1.05 eq), and EDCI (287 mg, 1.850 mmol, 1.05 eq) in DCM (15 mL) were 182	
stirred at 0°C for 15 mins under an atmosphere of N2. The appropriate sulfonamide 183	
(1.769 mmol, 1.0 eq) was added and the mixture stirred for 20 h at room temperature. 184	
The reaction mixture was poured into 2M aqueous HCl (20 mL) and extracted with 185	
dichloromethane (3 x 60 mL). The organic extracts were then combined and washed 186	
with saturated brine solution, before drying over magnesium sulfate. Following filtration, 187	
the solvent was removed under vacuum. Finally, purification by column 188	





1H NMR:  (400 MHz, CDCl3) 0.86 (d, 6H, 6.69 Hz), 1.09 – 1.19 (m, 2 H), 1.20 – 1.44 194	
(m, 8 H), 1.45 – 1.63 (m, 3 H), 2.36 (t, 2H, J = 7.20 Hz), 3.32 (s, 3H), 8.26 (bs, 1H). 195	
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13C NMR:  (100 MHz, CDCl3) 18.79, 22.65, 27.32, 27.35, 27.95, 28.87, 29.03, 29.66, 196	
38.96, 41.77, 73.55, 94.43, 150.55. 197	
IR:  (cm-1): 3237, 2923, 2852, 2229, 1688, 1435, 1334, 1325, 1145, 976, 882. 198	





1H NMR (400 MHz, CDCl3) δ 0.85 (d, 6H, J=6.63 Hz), 1.08-1.19 (m, 2H), 1.19-1.29, (m, 204	
6H), 1.29-1.39 (m, 2H), 1.45-1.57 (m, 3H), 2.29 (t, 2H, J=7.12 Hz), 7.52-7.61 (m, 2H), 205	
7.67 (t, 1H, J=7.44 Hz), 8.08 (d, 2H, J=7.41 Hz). 206	
13C NMR (75 MHz) 18.75, 22.65, 27.37, 27.32, 27.94, 28.83, 29.01, 29.63, 38.95, 207	
73.68, 93.94, 128.48, 129.05, 134.24, 138.21, 149.60. 208	
IR (ATR) max cm-1 566, 587, 685, 737, 866, 1057, 1089, 1163, 1218, 1351, 1433, 209	
1450, 1671, 2226, 2855, 2924, 3219. 210	
HRMS (ESI-TOF) m/z: [M + 1] Calcd for C19H28NO3S 350.1784; Found, 350.1783. 211	
 212	
N-((2-Bromophenyl)sulfonyl)-11-methyldodec-2-ynamide (3g) 213	
Yield: 51%  214	
1H NMR:  (400 MHz, CDCl3) 0.79 (d, 6H, J = 6.65 Hz), 1.02 – 1.11 (m, 2H), 1.13 – 215	
1.33 (m, 8H), 1.38 – 1.52 (m, 3H), 2.23 (t, 2H, J = 7.19 Hz), 7.38 – 7.48 (m , 2H), 7.68 216	
(dd, 1H, J = 1.68, 7.50 Hz), 8.22 (dd, 1H, J = 1.94, 7.76 Hz), 8.54 (bs, 1H). 217	
13C NMR:  (100 MHz, CDCl3) 18.82, 22.66, 27.30, 27.31, 27.94, 28.84, 29.02, 29.66, 218	
38.97, 73.48, 94.69, 120.23, 127.78, 133.41, 135.04, 135.30, 137.35, 149.35. 219	
IR:  (cm-1): 3219, 2952, 2917, 2850, 2228, 1697, 1427, 1348, 1163, 1052, 883. 220	
HRMS (ESI-TOF) m/z: [M + 1] Calcd for C19H27BrNO3S: 428.0890; Found 428.0878. 221	
 222	
N-(Cyclopropylsulfonyl)-11-methyldodec-2-ynamide (3h) 223	
Yield: 22%  224	
1H NMR:  (400 MHz, CDCl3) 0.86 (d, 6H, J = 6.57 Hz), 1.11 – 1.19 (m, 4H), 1.20 – 225	
1.45 (m, 10H), 1.46 – 1.66 (m, 3H), 2.36 (t, 2H, J = 7.19 Hz), 2.95 (tt, 1H, J = 3.34, 226	
4.74 Hz), 8.02 (bs, 1H). 227	
13C NMR:  (100 MHz, CDCl3) 6.46, 14.11, 18.80, 22.66, 27.38, 28.88, 29.01, 29.24, 228	
29.37, 31.50, 31.84, 73.70, 77.23, 150.16. 229	
IR:  (cm-1): 3222, 2925, 2855, 2228, 1682, 1433, 1345, 1148, 880. 230	




General procedure for the preparation of BDSF analogues 4a-4d and DSF 233	
analogues 4e-4h: 234	
Lindlar’s catalyst (100 mg) and the appropriate acylsulfonamide (0.045 mmol, 1.0 eq) 235	
were added to dichloromethane (6 mL). This solution was shaken vigorously in a 60 236	
PSI hydrogen atmosphere for 6 h using a Parr hydrogenator. The crude mixture was 237	
filtered and purified by careful column chromatography on silica gel using MeOH-DCM 238	
(0:100-1:99) to afford the target compounds. 239	
 240	
(Z)-N-(Methylsulfonyl)dodec-2-enamide (4a) 241	
Yield: 47%  242	
1H NMR:  (400 MHz, CDCl3) 0.80 (t, 3H, J = 6.62 Hz), 1.12 – 1.30 (m, 12H), 1.33 – 243	
1.42 (m, 2H), 2.62 (q, 2H; J = 7.30 Hz), 3.27 (s, 3H), 5.63 (d, 1H; J = 11.28 Hz), 6.30 244	
(dt, 1H; J = 7.53, 11.28 Hz), 8.27 (bs, 1H). 245	
13C NMR: δ (100 MHz, CDCl3) 14.13, 22.68, 28.91, 29.29, 29.35, 29.40, 29.42, 29.51, 246	
31.88, 41.73, 118.61, 154.81, 163.81. 247	
IR:  (cm-1): 3268, 2918, 2848, 1696, 1629, 1435, 1398, 1323, 1260, 1174, 1109, 980, 248	
929, 864, 823, 640. 249	
 250	
HRMS (ESI-TOF) m/z: [M – 1] Calcd for C13H24NO3S 274.1482; Found 274.1472. 251	
 252	
(Z)-N-(Phenylsulfonyl)dodec-2-enamide (4b) 253	
Yield: 92%  254	
1H NMR:  (400 MHz, CDCl3) 0.80 (t, 3H, J = 6.8 Hz), 1.059 – 1.348 (m, 14 H), 2.516 255	
(q, 2H, J = 7.2 Hz). 256	
 5.62 (d, 1H; J = 11.44 Hz), 6.18 (dt, 1H; J = 7.2, 11.44 Hz), 7.49 (t, 2H, J = 7.7 Hz), 257	
7.58 (t, 1H; J = 7.40), 7.98 – 8.05 (m, 2H), 8.36 – 8.59 (bs, 1H). 258	
13C NMR: δ (100 MHz, CDCl3): 22.67, 24.31, 28.88, 29.24, 29.27, 29.30, 29.39, 29.48, 259	
31.87, 118.73, 128.30, 129.04, 133.94, 138.71, 154.10, 162.80. 260	
IR:  (cm-1): 3287, 2956, 2916, 2848, 1729, 1702, 1625, 1582, 1449, 1427, 1335, 1260, 261	
1174, 1082, 846. 262	






1H NMR:  (400 MHz, CDCl3): 0.80 (t, 3H, J = 6.72 Hz), 1.01 – 1.45 (m, 16H), 2.48 (dq, 267	
2H, J = 1.29, 7.61 Hz), 5.69 (d, 1H, J = 10.86 Hz), 6.05 – 6.44 (m, 1H), 7.37 – 7.51 (m, 268	
2H), 7.63 (d, 1H, J = 7.67 Hz), 8.28 (dd, 1H, J = 1.68, 7.94 Hz), 8.51 (bs, 1H). 269	
13C NMR: δ (100 MHz, CDCl3): 14.13, 22.67, 28.85, 29.20, 29.27, 29.33, 29.37, 29.47, 270	
31.87, 118.55, 120.09, 127.96, 133.27, 134.80, 135.22, 137.71, 154.52, 162.67. 271	
IR:  (cm-1): 3224, 2918, 2848, 1704, 1637, 1576, 1431, 1341, 1280, 1252, 1184, 1139, 272	
1095, 799, 701. 273	
HRMS (ESI-TOF) m/z: [M – 1] Calcd for C18H25BrNO3S 414.0744; Found 414.0728. 274	
 275	
(Z)-N-(Cyclopropylsulfonyl)dodec-2-enamide (4d) 276	
Yield: 59%  277	
1H NMR:  (300 MHz, CDCl3): 0.87 (t, 3H, J = 6.62 Hz), 1.17 - 1.08 (m, 2H), 1.51 - 1.19 278	
(m, 16 H), 2.69 (dq, J = 7.36, 1.74 Hz), 3.04 - 2.94 (m, 1H), 5.71 (dt, J = 11.51, 1.74 279	
Hz), 6.34 (dt, J = 11.51, 7.54 Hz, 1H), 7.77 (bs, 1H). 280	
13C NMR:  (75 MHz, CDCl3): 6.30, 14.08, 22.65, 28.93, 29.26, 29.31, 29.34, 29.40, 281	
29.49, 31.51, 31.86, 118.78, 153.98, 163.33. 282	
IR:  (cm-1):3275, 2918, 2848, 1704, 1641, 1429, 1323, 1260, 1162, 1105, 1046, 950, 283	
885, 864, 803, 709. 284	
HRMS (ESI-TOF) m/z: [M + 1] Calcd for C15H28NO3S 302.1784; Found 302.1797. 285	
 286	
(Z)-11-Methyl-N-(methylsulfonyl)dodec-2-enamide (4e) 287	
Yield: 82%  288	
1H NMR:  (400 MHz, CDCl3) 0.86 (d, 6H, J = 6.62 Hz), 1.08 – 1.18 (m, 2H), 1.20 – 289	
1.37 (m, 8H), 1.39 – 1.57 (m, 3 H), 2.69 (dq, 2 H, J = 1.69, 7.53 Hz), 3.34 (s, 3H), 5.70 290	
(dt, 1H, J = 1.69, 11.33 Hz), 6.36 (dt, 1H, J = 7.53, 11.33 Hz), 8.22 (bs, 1H). 291	
13C NMR:  (100 MHz, CDCl3) 22.66, 27.36, 27.96, 28.91, 29.36, 29.40, 29.45, 29.81, 292	
39.01, 41.74, 118.59, 154.82, 163.77. 293	
IR:  (cm-1): 3268, 2954, 2921, 2851, 1698, 1633, 1442, 1399, 1323, 1175, 1108, 981, 294	
867. 295	




1H NMR (400 MHz, CDCl3) δ 0.86 (d, 6H, J=6.62 Hz), 1.08-1.17 (m, 2H), 1.17-1.31 (m, 300	
8H), 1.3-1.43 (m, 2H), 1.50 (h, 1H, J=6.57 Hz), 2.49-2.69 (m, 2H), 5.70 (d, 1H, J=11.39 301	
12	
	
Hz), 6.25 (dt, 1H, J=11.38 Hz, J=7.42 Hz), 7.52-7.61 (m, 2H), 7.65 (t, 1H, J=7.44 Hz), 302	
8.09 (d, 2H, J=7.48 Hz).  303	
13C NMR (75 MHz) 22.66, 27.35, 27.95, 28.90, 29.25, 29.30, 29.43, 29.78, 39.01, 304	
118.75, 128.30, 129.04, 133.93, 138.73, 154.07, 162.82.  305	
IR (ATR) max cm-1 563, 595, 684, 718, 756, 847, 864, 1088, 1140, 1187, 1346, 1438, 306	
1453, 1633, 1696, 2851, 2919, 3278. 307	
HRMS (ESI-TOF) m/z: [M + 1] Calcd for C19H30NO3S 352.1941; Found, 352.1938. 308	
 309	
(Z)-N-((2-Bromophenyl)sulfonyl)-11-methyldodec-2-enamide (4g) 310	
Yield: 85%  311	
1H NMR:  (400 MHz, CDCl3) 0.85 (d, 6H, J = 6.58 Hz), 1.07 – 1.29 (m, 10 H), 1.30 – 312	
1.40 (m, 2H), 1.49 (sep, 1H, J = 6.66 Hz), 2.55 (dq, 2H, J = 1.26, 7.37 Hz), 5.75 (dt, 313	
1H, J = 1.26, 11.41 Hz), 6.28 (dt, 1H, J = 7.37, 11.41 Hz), 7.47 (dt, 1H, J = 1.57, 7.76 314	
Hz), 7.54 (dt, 1H, J = 1.09, 7.78 Hz), 7.74 (dd, 1H, J = 1.09, 7.88 Hz), 8.35 (dd, 1H, J = 315	
1.57, 7.82 Hz), 8.64 (bs, 1H). 316	
13C NMR:  (100 MHz, CDCl3) 22.66, 27.34, 27.95, 28.85, 29.21, 29.34, 29.41, 29.76, 317	
39.00, 118.51, 120.04, 127.97, 133.26, 134.78, 135.20, 137.77, 154.51, 162.55. 318	
IR:  (cm-1): 3227, 2952, 2917, 2848, 1706, 1642, 1434, 1341, 1186, 1097, 873. 319	
HRMS (ESI-TOF) m/z: [M + 1] Calcd for C19H29BrNO3S: 430.1046; Found 430.1041. 320	
 321	
(Z)-N-(Cyclopropylsulfonyl)-11-methyldodec-2-enamide (4h) 322	
Yield: 75%  323	
1H NMR:  (400 MHz, CDCl3) 0.85 (d, 6H, J = 6.45 Hz), 1.09 – 1.18 (m, 4 H), 1.20 – 324	
1.36 (m, 8H), 1.36 – 1.56 (m, 5 H), 2.69 (dq, 2H, J = 1.53, 7.46 Hz), 2.94 – 3.04 (tt, 1H, 325	
J = 3.29, 4.78 Hz), 5.72 (dt, 1H, J = 1.53, 11.37 Hz),  6.34 (dt, 1H, J = 11.3, 7.46 Hz), 326	
8.12 (bs, 1H). 327	
13C NMR:  (100 MHz, CDCl3) 6.32, 22.66, 27.36, 27.96, 28.95, 29.35, 29.46, 29.81, 328	
31.47, 39.02, 118.80, 154.08, 163.52. 329	
IR:  (cm-1): 3287, 2958, 2918, 2850, 1706, 1640, 1416, 1323, 1106, 861 330	
HRMS (ESI-TOF) m/z: [M + 1] Calcd for C16H30NO3S 316.1941; Found 316.1940. 331	
 332	
Bacterial strains  333	
Bacteria used in this study include the species of the Burkholderia cepacia complex 334	
(BCC) Burkholderia cepacia (Bc) strain R6193, Burkholderia cenocepacia (Bcc) strain 335	
289, Burkholderia multivorans (Bm) strain B10  and the representative 336	
Stenotrophomonas maltophilia (Sm) strains K279a (belonging to the rpf-1 337	
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subpopulation) and D457 (belonging to the rpf-2 subpopulation) [26]. To detect DSF 338	
production and inhibition, the reporter strain Xanthomonas campestris pv campestris 339	
(Xc) 8523 pL6engGUS [40] was used. More detailed information can be found in 340	
Supplementary Table 1.  341	
 342	
Biofilm inhibition  343	
The inhibitory effect of the compounds on biofilm formation in Sm and BCC organisms 344	
was investigated on a polystyrene surface using 96-well microtitter non-treated plates 345	
(BrandTech 781662). Briefly, 200 µl of bacterial cultures in LB medium adjusted to an 346	
optical density (OD620nm) of 0.05 containing each compound at either 10 µM or 50 µM 347	
concentration were poured into wells and the plates were incubated for 24 h at 37 ºC. 348	
Control wells contained the same volume of the solvent DMSO. The next day, bacterial 349	
growth of biofilm plates was estimated by measuring the optical density of the wells at 350	
620 nm. Biofilm plates were then rinsed with PBS, fixed at 60 °C for 1 h and stained for 351	
15 min with 200 µl of crystal violet 0.1% (CV). The dye was removed and the plates 352	
were washed with distilled water and dried at 37 ºC for 30 min. CV (corresponding to 353	
the bacterial biomass adhered to the wells) was dissolved in 250 µl of 30% acetic acid 354	
for 15 min, and the optical density of the extracted dye was measured at 550 nm. 355	
Biofilm formation (OD550nm of CV) was normalized by cell growth (OD620nm) and reported 356	
as relative biofilm formation in percentage. Bacterial biofilm formation in the presence 357	
of the different compounds was compared to those containing the same volume of 358	
DMSO, which corresponded to 100% biofilm formation. Eight wells per compound per 359	
strain were used and the experiment was performed by triplicate. Statistical 360	
significance was analysed by the one-way ANOVA test. 361	
 362	
Antimicrobial susceptibility testing 363	
Minimal inhibitory concentration (MIC) of Stenotrophomonas and Burkholderia isolates 364	
to colistin in combination with the compound at a fixed dose of 10 µM or 50 µM were 365	
determined by the broth microdilution (BMD) method in cation-adjusted Muller Hinton 366	
Broth (CAMHB) in accordance with CLSI/EUCAST recommendations [41,42,43]. 367	
Breakpoint values were inferred by measuring the absorbance of the wells at 550 nm, 368	
and MICs were interpreted as those antibiotic concentrations that reduced ≥80% of 369	
bacterial growth compared to the positive control. All experiments were performed by 370	





Overnight cultures in CAMHB were diluted (1/100) in 10 mL of the same medium and 374	
incubated at 37ºC and 250 rpm to an optical density (OD620nm) of 0.2. Kill kinetics were 375	
then initiated by the addition of the antibiotic colistin (concentration corresponding to 376	
the MIC in combination with the effective adjuvant) and the adjuvant at 50 µM 377	
concentration. Bacterial survival was monitored every 15 minutes during 2 h by plating 378	
serial dilutions on MH agar medium and expressed in percentage in relation to time 379	
point 0. Three replicates of each culture set were performed and the statistical analysis 380	
was calculated by the two-tailed unpaired t-test. 381	
 382	
DSF and BDSF Bioassay 383	
To evaluate the potential quorum sensing inhibitory effect of the compounds on DSF 384	
production in S. maltophilia K279a, the DSF bioassay using the reporter strain 385	
Xanthomonas campestris pv. campestris 8523 pL6engGUS [40] was used. The 386	
reporter strain was cultured overnight in 10 ml of NYG medium (2% glycerol, 0.5% 387	
peptone and 0.3% yeast extract) containing 10 µg/ml of tetracycline to an OD620nm of 388	
0.7. Then, cells were centrifuged and resuspended in 1 ml of fresh medium and added 389	
to 100 ml NYGA medium with 1% of Agar Noble (BD Difco) and 80 µg/ml of X-Glu (5-390	
Bromo-4-chloro-3-indolyl ß-D-glucuronide sodium salt) (Sigma) and plated into petri 391	
plates. Then, an adjusted culture of the DSF-producer strain K279a (OD550nm of 0.5) 392	
was used to seed a confluent culture onto the reporter plate by using a cotton stick. 393	
After drying the plates, 1 µl of each antagonist stocked at 5 mg/ml in DMSO was 394	
inoculated onto the double-cultured plate containing the DSF-reporter strain (Xcc 8523 395	
pL6engGUS) into the agar and the DSF-producer strain (Sm K279a) onto the agar. 396	
Plates were incubated at 28ºC for 24 h and the presence of uncoloured halos indicated 397	
inhibition of DSF synthesis in Sm K279a.  398	
1 µl of DSF and BDSF signals at the same stock concentration were spotted onto 399	
regular bioassay plates to validate their biological activity. 400	
Sm and Bc strains used in this study were also tested on the regular bioassay by pin 401	
inoculation.  402	
 403	
In vivo efficacy using Galleria mellonella 404	
Larvae of Galleria mellonella were obtained from our own hatchery, which was 405	
established in collaboration with Professor Fernando García del Pino from the Zoology 406	
Department at the Universitat Autonoma de Barcelona.  407	
To prepare bacterial inoculums, Sm and BCC isolates were grown overnight in 10 ml of 408	
BD Brain Heart Infusion (BHI) medium at 37 ºC in a rotary shaker. Then, cells were 409	
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centrifuged, washed in PBS and adjusted to contain ≈105 cells in a dose of 5 µl. The 410	
bacterial burden of the doses was confirmed by plating on BHI medium.  411	
Thirty larvae per group were infected via left proleg with the aforementioned inoculum 412	
and incubated at 30 ºC for 1 h. Then, groups of infected larvae were treated by 413	
injecting via right proleg 5 µl of a PBS suspension containing either: i) DMSO 414	
(untreated group), ii) DMSO + colistin (colistin-treated group), or iii) compound + 415	
colistin (enhanced colistin-treated group).  416	
To treat Sm K279a infections, single doses of 3.2 mg/kg of colistin and 21.52 mg/kg of 417	
4g (corresponding to the in vitro colistin MIC of 4 µg/ml in combination with 50 µM 4g) 418	
was used. To treat larvae infected with Sm D457, single doses of 3.2 mg/kg of colistin 419	
and 20.82 mg/kg of 4c (corresponding to the in vitro colistin MIC of 4 µg/ml in 420	
combination with 50 µM 4c) were administered. Treatment of Bc R6193 infections was 421	
conducted by injecting single doses of 102.4 mg/kg of colistin and 21.52 mg/kg of 4g 422	
(corresponding to the in vitro colistin MIC of 128 µg/ml in combination with 50 µM 4g). 423	
An additional treatment with 102.4 mg/kg of colistin in combination with 4b at 16.87 424	
mg/kg was also applied to larvae infected with Bc R6193 (data not shown).  425	
Experiments were performed by triplicate on different occasions using different batches 426	
of insects. Kaplan–Meier survival curves were plotted using GraphPad Prism 5.0a and 427	
survival analysis and statistical significance was determined using the log-rank test. 428	
 429	
Toxicity by the MTT assay 430	
The toxicity of the compounds was assessed in vitro on human proximal tubule cells 431	
(HK-2) by the EZ4U cell proliferation assay (Biomedica) following the manufacturer’s 432	
instructions. In brief, HK-2 cells were cultured in DMEM/F12 with 10% FCS and 1% 433	
penicillin/streptomycin (GIBCO, Invitrogen) and seeded at a concentration of 4000 cells 434	
per well in 96-well tissue culture plates with clear bottoms (Falcon®), and plates were 435	
incubated overnight at 37 °C in a 5% CO2 atmosphere. The next day, the medium was 436	
released and the DSF and BDSF derivatives were applied onto wells seeded with HK-2 437	
cells at 50 µM concentration in 200 µl volume of DMEM/F12. Cell viability was 438	
determined by means of EZ4U assay after 24 and 48 h of exposure to the compounds, 439	
according to the manufacturer’s instruction. Plates were read using a microplate reader 440	
(Victor 3, Wallac) at a wavelength of 450 nm and 620 nm, the latter used as a 441	
reference. The results were expressed as percentage of cell survival using untreated 442	
cells as control. Eight replicates per compound were performed and the experiment 443	
was conducted in two independent occasions. Statistical significance was measured by 444	





Results and discussion 448	
Chemistry 449	
Initially, a series of unbranched sulfonamide derivatives of BDSF was prepared. 450	
Starting from commercially available 1-undecyne (1a), dodec-2-ynoic acid (2a) was 451	
obtained by the lithiation of 1a followed by addition of carbon dioxide gas (Figure 2). 452	
Early in our studies, we discovered that direct coupling of BDSF with a sulfonamide led 453	
to a mixture of cis- and trans-unsaturated products, which were often difficult to 454	
separate. For that reason, we adopted a strategy whereby sulfonamide coupling would 455	
preceed a stereoselective, partial hydrogenation to the target. Accordingly, 2a was 456	
subjected to EDCI-mediated coupling with aliphatic and aromatic sulfonamides to 457	
afford acylsulfonamides 3a-3d. Finally, partial hydrogenation of 3a-3d in the presence 458	
of Lindlar’s catalyst afforded BDSF analogues 4a-4d exclusively as their cis-isomers. 459	
The preparation of the corresponding DSF analogues incorporating an 11-methyl group 460	
was achieved in a similar manner, but starting from 10-methylundec-1-yne (1b). The 461	
synthesis of 1b has been previously reported and relies on an alkyne zipper reaction to 462	
furnish the requisite terminal alkyne [44]. As before, lithiation of 1b followed by addition 463	
of carbon dioxide furnished propargylic acid 2b. EDCI coupling of 2b with the 464	
appropriate sulfonamide furnished acylsulfonamides 3e-3h. Semi-hydrogenation of 3e-465	
3h produced DSF analogues 4e-4h with the required Z-configuration. For comparison 466	
purposes, pure samples of BDSF and DSF were prepared by the partial hydrogenation 467	


















1a : R = H
1b : R = Me
4a : R = H; R' = Me
4b: R = H; R' = Ph
4c : R = H; R' = 2-Br-C6H4
4d : R = H; R' = Cyclopropyl
4e : R = Me; R' = Me
4f: R = Me; R' = Ph
4g : R = Me; R' = 2-Br-C6H4




2a : R = H





3a : R = H; R' = Me
3b : R = H; R' = Ph
3c : R = H; R' = 2-Br-C6H4
3d : R = H; R' = Cyclopropyl
3e : R = Me; R' = Me
3f : R = Me; R' = Ph
3g : R = Me; R' = 2-Br-C6H4









The effect of our library was tested against clinically relevant phenotypes regulated by 474	
QS in isolates of the two human pathogens which exploit DSF communication, namely 475	
S. maltophilia (Sm) and B. cepacia complex (BCC). To achieve representative results 476	
in terms of QS regulation in Sm, two clinical isolates belonging to the rpf-1 477	
subpopulation (K279a) and the rpf-2 subpopulation (D457) [26] were investigated. For 478	
the BCC, three clinical isolates belonging to the species B. cepacia (Bc R6193), B. 479	
cenocepacia (Bcc 289) and B. multivorans (Bm B10) were selected (Supplementary 480	
Table 1).  481	
 482	
Biofilm assays in the presence of our BDSF and DSF analogues revealed that 4g was 483	
the most potent inhibitor, decreasing biofilm formation in all Sm and BCC specimens at 484	
50 µM on a polystyrene surface (Figure 3). Similarly, DSF-derivative 4g, as well as its 485	
BDSF analogue 4c, displayed an inhibitory effect against Bc. Bcc and Bm proved even 486	
more sensitive with compounds 4b-h inhibiting biofilm production in these species. 487	
Furthermore, a significant effect at 10 µM concentration was observed for 4c, 4d, 4f 488	
and 4g in Bcc and likewise for 4c, 4f and 4g in Bm. In Bc, the presence of a 489	
brominated aromatic ring appears to be important for antibiofilm activity, since both 4c 490	
and 4g contain such a motif (Figure 2). This molecular feature is also important for 491	
biofilm inhibition in Bcc and Bm isolates, with these compounds displaying noticeably 492	
higher activity. In Sm, the presence of a methyl group on C11 appears to be a 493	
additional prerequisite for activity, with only 4g displaying an inhibitory effect while its 494	
des-methyl analogue 4c was inactive.   495	
Sulfonamides 4b, 4c, 4f and 4g also moderately retarded growth of Sm isolates at 50 496	
µM after 24 h incubation at 37 ºC (Supplementary Figure 1 A-B). Interestingly, phenyl-497	
substituted 4f displayed a small, but significant, inhibitory effect at the lower 498	
concentration of 10 µM. For BCC isolates, 4c, 4d, 4f and 4g slightly reduced growth in 499	





Figure 3. Inhibitory effect of 4a-4h at 10 µM and 50 µM on the growth of Sm K279a 503	
(A), Sm D457 (B), Bc R6193 (C), Bcc 289 (D) and Bm B10 (E) in 96-well plate after 24 504	
h incubation in LB at 37ºC. * P<0.01; ** P<0.001. 505	
 506	
As pathogens, Sm and BCC compensate their limited pathogenicity with a strong ability 507	
to form biofilms, which notably contributes to their MDR capacity and may result in 508	
chronic infection. To date, few studies have been conducted with the aim of identifying 509	
or designing new antibiofilm compounds against BCC and Sm. Certain DSF-related 510	
fatty acids display intrinsic antibiofilm activity. Of these, cis-DA produced by 511	
Pseudomonas aeruginosa (Pa), has been shown to disperse mature biofilms of diverse 512	
gram-negative (GN) and gram-positive (GP) pathogens [34]. In Sm rpf-1 as in Xc, DSF 513	
appears to prevent biofilm formation. Our work confirms that DSF-based bioisosteric 514	
analogues can significantly inhibit biofilm formation in both Sm and BCC. 515	
 516	
Given the moderate inhibitory effect on bacterial growth exhibited by certain 517	
compounds (e.g., 4b, 4c, 4d, 4f and 4g against Sm and Bcc isolates), we wondered 518	
whether our molecules might possess intrinsic antimicrobial activity. However, this 519	
hypothesis was subsequently discounted as minimum inhibitory concentration (MIC) 520	
values above 500 µg/ml (corresponding to 1-3 mM) were recorded for all compounds 521	
including the natural signals DSF and BDSF against Sm and Bc R6193 isolates 522	
(Supplementary Figure 2). The observed effects were likely attributable to the 523	




It has been reported that DSF induces resistance to various antibiotics, including 526	
polymyxin B, in Pseudomonas aeruginosa [45]. By contrast, DSF and related fatty 527	
acids enhance the activity of selected antibiotics against several other GN and GP 528	
pathogens [46]. Surprisingly, the antibiotic colistin has never been tested in 529	
combination with DSF or BDSF against Sm and BCC species.  530	
 531	
Colistin is a last-resort antibiotic that is administered to patients suffering from 532	
nosocomial infections caused by GN pathogens when no other option exists. Sm and 533	
BCC are typical MDR pathogens, which considerably limits the therapeutic possibilities. 534	
Members of BCC are intrinsically resistant to colistin primarily because of its LPS 535	
composition which prevents colistin binding and activity [47]. These bacterial species 536	
display additional population mechanisms such as heteroresistance [48] and adaptive 537	
resistance [49]. Higher degrees of colistin susceptibility are observed in Sm isolates, 538	
although an increasing incidence of colistin-resistance has been recently observed 539	
[50,51]. Recently, heterogeneous colistin resistance phenotypes have also been 540	
identified in Sm isolates [52]. Importantly, it has been observed that colistin treatment 541	
induces biofilm formation in Sm [52]. Moreover, horizontal transference of plasmid-542	
mediated colistin resistance genes among GN bacteria has also been reported, to the 543	
alarm of the scientific and medical communities [53]. 544	
Given that the Sm and BCC species are highly resistant to colistin monotherapy, we 545	
wondered whether the activity of colistin could be rescued by the addition of our DSF 546	
and BDSF derivatives. 547	
 548	
The MIC to colistin of the isolates was assessed by the broth microdilution method 549	
(BMD) [41,42] in the presence of 4a-4h at a fixed dose of 10 µM or 50 µM. As clinical 550	
breakpoints to colistin for Sm and BCC are not available (EUCAST),	 the breakpoint for 551	
P. aeruginosa (2 µg/ml) was instead used [43]. 552	
All six strains proved resistant to colistin with MICs of 16 and 64 in Sm K279a and Sm 553	
D457, respectively, and >256 µg/ml in the three BCC species (Table 1). None of our 554	
analogues increased resistance levels to colistin. In fact, most of the compounds, 555	
including the natural signalling molecules DSF and BDSF, reduced MIC values in 556	
comparison to the DMSO control for the majority of strains assayed. The observed 557	
enhancing effect was dose dependent and a generally greater MIC reduction was 558	
observed at 50 µM concentration. In Sm isolates, all of our molecules reduced MIC 559	
values 2- to 16-fold at 50 µM. The greatest reduction was observed in Sm D457 560	
challenged with 50 µM of 4c, which resulted in a MIC to colistin of 4 µg/ml. Aside from 561	
Sm D457 in the presence of 4b or 4e, co-administration of the remaining compounds at 562	
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50 µM reduced MICs of Sm resistant isolates below 8 µg/ml, a colistin concentration 563	
that can be readily reached with colistin inhalation therapy [54]. 564	
A 2- to 4-fold reduction of MIC values was also observed in Bc R6193 for 5 of the 8 565	
sulfonamides at 50 µM, although antibiotic concentrations remained very high (≥128 566	
µg/ml). In Bcc 289, all compounds resulted in decreased MICs, reaching a 16-fold 567	
reduction in the case of 4c. By contrast, Bm B10 did not respond to any colistin-568	
adjuvant combination with unaltered MICs recorded. 569	
In order to discard an unspecific enhancing effect of saturated fatty acids, palmitic 570	
(C12), lauric (C14) and stearic (C16) fatty acids were also tested at 50 µM in 571	
combination with colistin, with unaltered MICs observed for Sm and Bc R6193 strains 572	
(data not shown).  573	
The effect of 4a-4h was also investigated in combination with ciprofloxacin and 574	
sulfametoxazole/trimetroprim (SXT), two antibiotics used in the treatment of Sm and 575	
BCC infections. Although certain antibiotic-adjuvant combinations showed a 2-fold 576	
reduction in MICs, no major effect was recorded for any isolate (Supplementary Table 577	
2 and 3).  578	
 579	
To further investigate the bactericidal effect of our library in combination with colistin, 580	
time-kill curves were performed for those compounds displaying an appreciable MIC 581	
reduction against Sm K279a, Sm D457 and Bc R6193. In cases where two or more 582	
analogues displayed similar colistin-enhancing activity, those compounds also 583	
exhibiting antibiofilm activity were selected (e.g., Sm K279a with 4g). Colistin 584	
concentrations were selected based on the corresponding MIC values in combination 585	
with the appropriate compound. Following this criteria, Sm K279a was challenged with 586	
50 µM of 4g plus 4 µg/ml of colistin, Sm D457 was treated with 50 µM of 4c plus 4 587	
µg/ml of colistin, and Bc R6193 was challenged with 50 µM of 4g plus 128 µg/ml of 588	
colistin. As shown in Figure 4 panels A-C, 4g and 4c in combination with 4 µg/ml of 589	
colistin significantly reduced the survival of Sm K279a and D457 respectively. By 590	
contrast, a combination of 4g with 128 µg/ml of colistin did not decrease the survival of 591	
Bc R6193.  592	
Our results indicate that for Sm, the addition of our compounds to colistin not only 593	
reduces MIC values, but also potentiates its bactericidal activity. In Bc, however, the 594	
colistin-compound combination solely potentiates its growth inhibitory effect. These 595	
findings are in line with those obtained by Deng and collaborators [46] who observed 596	




Table 1. MICs to colistin of S. maltophilia and BCC isolates in the presence of the 599	
compounds at a fixed dose of 10 and 50 µM by the BMD method. 600	
   
colistin MIC (µg/ml)  
   





K279a D457 B. cepacia R6193 B. cenocepacia 289 B. multivorans B10
w/o  
  
16 64 >512 >256 >256 
DMSO 
  






















































































8 32 256 >256 >256 
    50   4 8  256 32 >256 
ND: Not determined.  601	




Figure 4. Time kill-curves of the Sm K279a (A), Sm D457 (B) and Bc R6193 (C) in the 606	
presence of the appropriate colistin-adjuvant combination (** P<0.001).  607	
 608	
In an attempt to assess whether our compounds may interfere with QS communication, 609	
we designed a negative bioassay to test our library’s inhibitory effect on DSF synthesis 610	
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in Sm strain K279a (see materials and methods for details). As shown in Figure 5, 7 of 611	
the 8 sulfonamides produced a white halo indicating inhibition of DSF production in Sm 612	
K279a. The DSF-inhibitory compounds included 4a-4e and 4g-4h, while 4f produced a 613	
blue halo indicating overactivation of the reporter strain. Such activation could be 614	
attributable to either intrinsic activity of 4f on the bioassay or an inducing effect on the 615	
DSF synthesis of Sm K279a. Of the putative antagonists, 4a, 4d, 4e and 4h generated 616	
the largest halos of inhibition. It is interesting to note that alkyl-subtituted, rather than 617	
aryl-substituted, sulfonamides produced the larger halos of inhibition. Methyl-618	
substituted sulfonamides 4a and 4e and cyclopropyl-substituted sulfonamides 4d and 619	
4h appear to be the more effective inhibitors in this context. Of these, the BDSF 620	
analogues 4a and 4d exhibit greater inhibition than the corresponding DSF derivatives 621	
4e and 4h.   622	
 623	
As expected, DSF and BDSF effected activation of the reporter strain. To determine 624	
whether or not the white halo corresponded to growth inhibition of the Xc reporter 625	
strain, an equal volume of the sulfonamides was added to liquid cultures and the 626	
optical density of the strains was read after incubation under the same conditions. 627	
Although some compounds slightly reduced growth of the reporter strain, no correlation 628	
was observed between the inhibitory halo in the bioassay and the growth inhibition in 629	
the liquid culture (Supplementary Figure 2). These results, in combination with the MIC 630	
experiments of the compounds alone (Supplementary Figure 1), support the 631	
hypothesis that our molecules affect DSF synthesis independently of bacterial growth.  632	
 633	
The same bioassay approach was adopted for Sm D457 and Bc R6193 strains to 634	
measure inhibition of DSF synthesis. As previously reported, however, D457 635	
(harbouring the cluster variant rpf-2) does not produce detectable levels of DSF under 636	
these conditions [26,27] (Figure 5C). Although BDSF production was observed after 637	
pin-inoculation of Bc in the regular bioassay (Figure 5C), the confluent growth of Bc on 638	
the negative bioassay plate did not give a blue background corresponding to BDSF 639	





Figure 5. Determination of the inhibitory effect of the compounds on the DSF synthesis 643	
of Sm K279 using a bioassay (A and B). DSF production by Sm K279a, Sm D457 and 644	
Bc R6193 (C). Activity of synthetic DSF (D) and BDSF (E) on the bioassay.  645	
	646	
To the best of our knowledge, this is the first time that interference with DSF-QS has 647	
been achieved in Sm [55]. Nonetheless, further research should be performed to 648	
validate DSF inhibition in larger liquid cultures and identify the exact mechanism by 649	
which these DSF and BDSF antagonists influence signal synthesis in Sm K279a.  650	
 651	
Based on the encouraging results from the in vitro experiments, we next investigated 652	
our compounds’ activity in vivo using the Galleria mellonella model of infection. To that 653	
end, we selected the strain-compound combination that exhibited greatest antibiofilm 654	
and colistin enhancing activity in Sm K279a, Sm D457 and Bc R6193 isolates. 655	
Accordingly, one group of 30 larvae was infected with 1-3 x 105 cfu of Sm K279a and 656	
treated with colistin alone (3.2 mg/kg) or in combination with 4g (21.5 mg/kg). A second 657	
group was infected with the same inoculum of Sm D457 and treated with colistin alone 658	
(3.2 mg/kg) or in combination with 4c (20.8 mg/kg). The final group was infected with 659	
an equal dose of Bc R6193 and challenged with colistin alone (102.4 mg/kg) or in 660	
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combination with 4g (21.5 mg/kg). As with the time-kill curve experiments, treatment of 661	
Bc infections either with colistin alone or in combination did not result in a significant 662	
change in larvae survival. This result further confirms that colistin is not a suitable 663	
choice for treating Bc infections and that our analogues do not significantly increase 664	
colistin potency (data not shown). By contrast, 4g increased the in vivo efficacy of 665	
colistin for Sm infections, being particularly effective against infections caused by the 666	
strain K279a (Figure 6A). Although 4c was partially effective in the treatment of Sm 667	
D457 infections, the results were not significant (Figure 6B). These in vivo results are 668	
in line with those obtained in the MIC and time-kill curves experiments, with 4g again 669	
proving to be the most effective agent against Sm K279a.  670	
 671	
The increased efficacy observed for 4g against Sm K279a infections may be 672	
attributable to a multifactorial effect. On the one hand, the more lipophilic nature of 673	
certain analogues may facilitate destabilization of the bacterial membranes, thereby 674	
potentiating colistin activity. Recently, it has been reported that addition of exogenous 675	
polyunsaturated fatty acids to Klebsiella pneumoniae decreased the MICs to polymyxin 676	
B and colistin, and inhibited biofilm formation due to interference with membrane 677	
phospholipids [56]. Likewise, deletion of rpfF-1 (the variant present in K279a) but not 678	
rpfF-2 (the variant of D457) leads to bacterial attenuation using the Caenorhabditis 679	
elegans and Zebrafish models, probably due to the inherent inactivity of RpfF-2 in the 680	
conditions tested [26].  681	
Colistin was withdrawn from the clinical antibiotic pipeline because of its nephrotoxicity 682	
in the early 1980s, but has been recently reintroduced due to the emergence of MDR 683	
gram-negative bacteria [57]. Therefore, administration of colistin in combination with 684	
adjuvants that potentiate its activity at lower dosages is an interesting strategy. With 685	
this in mind, we measured the in vitro toxicity of our analogues using HK-2 human 686	
kidney cells [58]. The MTT assay revealed that none of the compounds display 687	





Figure 6. In vivo efficacy of 4g and 4c in combination with colistin against Sm K279a 691	
(A) and Sm D457 (B).  MTT cytotoxic assay of 4a-4h on HK-2 human kidney cells after 692	





The quorum sensing (QS) signals DSF and BDSF produced by Stenotrophomonas 696	
maltophilia (Sm) and species of the Burkholderia cepacia complex (BCC) participate in 697	
the regulation of clinically relevant phenotypes such as biofilm formation, antimicrobial 698	
resistance and bacterial virulence.  699	
In this study, we have synthesized a series of DSF and BDSF derivatives containing 700	
bioisosteric sulfonamides in place of the original carboxylic acid groups. We have 701	
investigated their efficacy as biofilm inhibitors, antimicrobial adjuvants and QS 702	
antagonists against clinical isolates of Sm and BCC, which are multidrug resistant.  703	
Biofilm assays for Sm identified 4g as the most potent antibiofilm agent against the two 704	
representative strains K279a and D457. All of our compounds decreased MICs to 705	
colistin in Sm isolates. 4c was observed to be particularly effective against Sm D457 706	
causing a 16-fold MIC reduction (final MIC of 4 µg/ml). This was accompanied by an 707	
increase in bacterial mortality. In Sm K279a 4g, the most potent biofilm inhibitor, also 708	
displayed a reduced MIC to colistin (4-fold; 4 µg/ml) and a significant increase in its 709	
bactericidal effect. Remarkably, a majority of our compounds reduced MICs to colistin 710	
below 8 µg/ml, a concentration that is reachable by inhalation therapy. Furthermore, 711	
treatment of Galleria mellonella larvae infected with either Sm D457 or K279a with the 712	
appropriate colistin-analogue combination resulted in increased larval survival, to a 713	
significant extent when K279a was treated with 4g.  714	
Although most of our compounds reduced MICs to colistin in Bc and Bcc, they failed to 715	
fully rescue the activity of this antibiotic. However, biofilm production in the BCC 716	
isolates Bcc 289 and Bm B10 proved highly sensitive to our sulfonamides,  with 4c and 717	
4g displaying a significant inhibitory effect at 10 µm concentration. The shared 718	
bromophenyl motif in 4c and 4g appears key to their activity. 719	
Interestingly, all compounds except 4f appear to block DSF production in Sm K279a, 720	
with a noticeably greater inhibitory effect observed in the BDSF derivatives over their 721	
corresponding DSF analogues. This is the first time that interference with DSF-QS has 722	
been achieved in Sm.  723	
Overall, our results show that sulfonamide-containing bioisosteres of DSF and BDSF 724	
constitute a new family of bioactive agents with potential antibiofilm, antimicrobial and 725	
anti-QS effects. The novel analogues described in this study have been demonstrated 726	
to be effective against Sm MDR isolates. Future studies should be conducted to 727	
identify the precise mechanisms that underlie the variety of effects exhibited by these 728	
compounds in order to design more effective antimicrobial agents with a broader 729	





For the last seven decades, antibiotics have played a central role in medicine. Their 733	
discovery has rendered previously fatal infections easily treatable. To some extent, 734	
antibiotics have become victims of their own success, whereby widespread availability 735	
and inappropriate usage have promoted the growth of antimicrobial resistance. Indeed, 736	
such a scenario was predicted by Gerhard Domagk in his 1947 Nobel acceptance 737	
speech for discovering the first synthetic antibiotics. Currently, bacterial infections are 738	
responsible for 700,000 deaths around the globe each year. It is predicted that by 739	
2050, more than 10 million individuals will die as a result of AMR. Given the decreasing 740	
number of effective antibiotics and the difficulties associated with the development of 741	
new classes of antibiotics, it is clear that alternative strategies are required. One 742	
possible approach relies on targeting quorum sensing and bacterial intercellular 743	
communication. Interference with quorum sensing can display multiple effects including 744	
disruption of resistance mechanisms. Additionally, such an approach does not produce 745	
the same evolutionary pressure which is associated with antibiotic usage. Agents 746	
which inhibit quorum sensing could offer a new lease of life to both existing antibiotics 747	
and to those antibiotics which have fallen out of use. Combination therapies, such as 748	
colistin/DSF bioiostere regimen outlined in this work, have significant potential in this 749	
regard. Furthermore, compounds which disrupt quorum sensing constitute useful 750	
probes for elucidating the underlying basis of bacterial resistance and ultimately 751	
designing new strategies for subverting AMR. Similarly novel approaches will be 752	
required if we are to successfully tackle AMR into the future. 753	
 754	
SUMMARY POINTS 755	
- Sulfonamide-based bioisosteres of DSF and BDSF possess potential antibiofilm and 756	
anti-quorum sensing activity against Stenotrophomonas maltophilia (Sm) and the 757	
Burkholderia cepacia complex (BCC). 758	
- All of our compounds decrease MICs to colistin (2- to 16-fold) in Sm resistant isolates 759	
and a majority reduced MICs below 8 µg/ml, a concentration that is reachable by 760	
inhalation therapy. 761	
- The 2-bromophenyl-substituted DSF analogue also displays significant antibiofilm 762	
activity against Sm.  763	
-The majority of these novel compounds inhibit DSF production in Sm.	764	
- Treatment of Sm-infected Galleria mellonella with a combination of colistin and the 2-765	




-Most of our compounds reduce MICs to colistin in B. cepacia (Bc) and B. cenocepacia 768	
(Bcc), and the 2-bromophenyl-substituted DSF and BDSF analogues also exhibit 769	
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Sm - Stenotrophomonas maltophilia 804	
BCC -  Burkholderia cepacia complex 805	
Bc - Burkholderia cepacia  806	
Bcc - Burkholderia cenocepacia 807	
Bm - Burkholderia multivorans 808	
Xc - Xanthomonas campestris 809	
Pa - Pseudomonas aeruginosa 810	
rpf - Regulation of pathogenicity factors 811	
QS - Quorum sensing 812	
GN - Gram-negative 813	
GP - Gram-positive 814	
DSF - Diffusible signal factor  815	
BDSF - Burkholderia diffusible signal factor  816	
DA – Decenoic acid 817	
DMSO - Dimethyl sulfoxide 818	
BMD - Broth microdilution 819	
MIC - Minimal inhibitory concentration 820	
MDR - Multidrug resistance  821	
CAMHB - Cation-adjusted Muller Hinton Broth 822	
CV - Crystal violet 823	
LPS - Lipopolysaccharide 824	
EDCI - N-Ethyl-N´-(3-dimethylaminopropyl)carbodiimide 825	
DMAP – Dimethylaminopyridine 826	
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